Wells Fargo analyst Derek Archila maintained a Buy rating on Immunovant yesterday and set a price target of $45.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Derek Archila has given his Buy rating due to a combination of factors related to Immunovant’s ongoing developments and future potential. One of the key reasons is the progression of their IMVT-1402 pipeline, which is expected to be a significant catalyst for the company’s stock. The initiation of pivotal studies for IMVT-1402 in Graves’ disease and Sjögren’s syndrome, with anticipated results in the coming years, highlights the potential for substantial advancements.
Moreover, the upcoming data releases, including the open-label data for IMVT-1402’s D2T RA and CLE, are expected to be major catalysts in 2026. Immunovant’s strong cash position, reported at $599 million, is projected to support their operations through the release of crucial data in 2027. Archila also notes that the current stock price offers an attractive entry point for long-term investors, especially given the potential of the FcRn class, which could be a significant market opportunity.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $35.00 price target.
Based on the recent corporate insider activity of 60 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IMVT in relation to earlier this year.